Drug Topics
JANUARY 8, 2024
Advocates can amplify the voices of transgender patients as they overcome barriers to health care, said Molly Crowther in a conversation at the 2023 Healthcare Advocate Summit.
Pharmacy Times
JANUARY 8, 2024
Tune in to this episode of Pharmacy Focus for a deep dive into the world of independent pharmacists prescribing, featuring insights and expertise from Deeb Eid.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
JANUARY 8, 2024
Turn on your TV or open a web browser this January, and you’ll be bombarded with ads for fitness trackers, smart scales, health apps, and other digital innovations promising to streamline your journey to a happier and healthier you. It’s the time of year when we’re most susceptible to such messaging: Surveys show that at least one-third of our New Year’s resolutions focus on exercising, losing weight, or eating better.
Pharmacy Times
JANUARY 8, 2024
Pharmacists in community and retail practices are stepping out from behind the counter and becoming more involved in patient care.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
STAT
JANUARY 8, 2024
SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years. That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech.
Fierce Pharma
JANUARY 8, 2024
San Francisco—Nearly all top cancer drugmakers have struck deals in the sizzling antibody-drug conjugate field—but not Novartis. | Nearly all top cancer drugmakers have struck deals in the sizzling antibody-drug conjugate field—but not Novartis. On Monday, the Swiss pharma’s CEO Vas Narasimhan explained how he's resisted the temptation.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
JANUARY 8, 2024
Several U.S. lawmakers including Sen. Bernie Sanders (I-Vt.) are investigating the prices charged by four large drug companies for their asthma inhalers, arguing the devices unfairly cost Americans considerably more than what consumers pay in other countries. The lawmakers maintained that the companies — AstraZeneca , GSK , Teva Pharmaceutical , and Boehringer Ingelheim — charge between $200 and $600 in the U.S. for their inhalers, which are typically purchased monthly, but sell th
Pharmacy Times
JANUARY 8, 2024
Those who were exposed to the clinically acquired stomach bacteria had a 24% increased risk of Alzheimer disease after a decade of onset.
STAT
JANUARY 8, 2024
Medicare Advantage members continue to go to the doctor and get health care procedures a lot more than predicted, CVS Health executives said at the J.P. Morgan Healthcare Conference on Monday. A persistent theme for health insurance companies throughout 2023 has been their Medicare Advantage members using more care than their actuaries projected, which has been eating into the profits they get from federally funded health care premiums.
Pharmacy Times
JANUARY 8, 2024
Stress may have more of an effect on migraines than COVID-19 infection or vaccination.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
JANUARY 8, 2024
SAN FRANCISCO — Mayo Clinic has signed Silicon Valley tech startup Cerebras as its first generative AI partner, the health system announced Monday. The health system — known for its cutting-edge research and willingness to partner with tech companies — will give Cerebras millions of dollars to help build technology tools based on Mayo’s trove of de-identified patient data, leaders announced at the J.P.
Pharmacy Times
JANUARY 8, 2024
If vaccination coverage was increased by 100%, outpatient care could be reduced by 81.2%, hospitalizations by 91.7%, and deaths by 91.3%.
STAT
JANUARY 8, 2024
SAN FRANCISCO — If you learned anything about nonprofit hospitals on the first day of the J.P. Morgan Healthcare Conference, it’s that they’ve all but abandoned the prospect of making significant profit on patient care. Instead, they’re fully throwing their weight into other ways of making money — things like developing drugs or selling insurance.
Fierce Pharma
JANUARY 8, 2024
While some Merck & Co. investors may still get the heebie-jeebies when thinking about Keytruda’s patent cliff in 2028, but the company’s CEO Rob Davis now thinks “it’s just another year.” | While some Merck & Co. investors may still get the heebie-jeebies when thinking about Keytruda’s patent cliff in 2028, but the company’s CEO Rob Davis now thinks “it’s just another year.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
JANUARY 8, 2024
Recognizing that culture is a multifaceted concept can lead to more careful and thoughtful use of the term.
Fierce Pharma
JANUARY 8, 2024
It took Bristol Myers Squibb’s new CEO Chris Boerner 16 minutes into his 24-minute presentation to address the big news the company made last month, with its holiday
STAT
JANUARY 8, 2024
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday. JPM24 is ~here~ The J.P. Morgan Healthcare Conference is exhausting and wildly expensive — a rather apt metaphor for the health care system itself.
PharmExec
JANUARY 8, 2024
Huestis discusses the ways that quantum simulation and quantum systems can be used in areas such as drug discovery and the creation and protection of intellectual property in the life sciences industry.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
JANUARY 8, 2024
Johnson & Johnson is starting the year with a new corporate identi | Despite all the recent changes at Johnson & Johnson, the company maintains an aggressive outlook for its pharmaceuticals division. In fact, J&J's sales forecasts for some drugs come in vastly higher than analyst numbers.
STAT
JANUARY 8, 2024
Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion. It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year.
Pharmacy Times
JANUARY 8, 2024
The report allows management to provide guaranteed assessments throughout the screenings that could aid early detection, diagnosis, and lung cancer treatment.
Drug Topics
JANUARY 8, 2024
A study found that patients living in a food desert and in a less walkable neighborhood had an increased risk of gestational diabetes.
STAT
JANUARY 8, 2024
A group of academic hospitals and technology companies will form a new nonprofit venture to oversee a nationwide network of laboratories to test artificial intelligence tools designed for use in health care. The nonprofit will establish the laboratories at Mayo Clinic, Duke, Stanford, and other major universities and institutions around the country.
Fierce Pharma
JANUARY 8, 2024
Biopharma companies looking to maximize the visibility of their M&A activity often reveal deals during the J.P. Morgan Healthcare Conference. | In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity. The late surge of activity in 2023 also bodes well for a 2024 uptick, the group said.
STAT
JANUARY 8, 2024
Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development. The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference , extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.
Fierce Healthcare
JANUARY 8, 2024
SAN FRANCISCO — Real-world data and artificial intelligence are front and center among Mayo Clinic’s plans for the future. | The Minnesota nonprofit courted investors and other conference attendees Monday with details on its ongoing pilots and other AI initiatives.
STAT
JANUARY 8, 2024
SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two months. But in trying to sell the company to investors on Monday at the annual J.P. Morgan Healthcare Conference, he pointed to the company’s 150-year history. He spoke of the “next chapter” for BMS, which saw its stock fall 27% last year, and said that the company would be going through a “period of renewal.
Fierce Healthcare
JANUARY 8, 2024
Innovaccer, maker of digital tools for providers, has launched an AI assistant that transcribes, analyzes and summarizes conversations between providers and patients. | Sara Scribe prepares encounter notes and provides clinical insights into quality gaps, coding gaps and potential diagnoses for the clinician.
Drug Store News
JANUARY 8, 2024
Steve Deckard will transition to executive vice president of store operations and development, succeeding Steve Sunderland who is leaving the company Jan. 19.
Fierce Healthcare
JANUARY 8, 2024
SAN FRANCISCO — As many investors predicted, digital health funding took a dive in 2023 with startups bringing in $10.7 billion across 492 deals, representing the lowest amount of capital invested | Faced with tightening capital availability, startups got creative to stay afloat and looked for lifelines in 2023, according to Rock Health research analysts.
pharmaphorum
JANUARY 8, 2024
Stay up to date with the latest developments in clinical trials, including updates on Vicore, Mundipharma, Agios, Ultragenyx, EG 427, Orion, and MSD. Find out what these companies are working on and their potential impact on healthcare.
Fierce Healthcare
JANUARY 8, 2024
For the 2023 plan year, Aetna's performance in the annual Medicare Advantage star ratings took a massive hit, with just 21% of its members enrolled in plans that earned a score of four stars or mor | After a rough showing a year ago, Aetna bounced back for 2024, and was one of the stronger performers in the latest star ratings.
STAT
JANUARY 8, 2024
Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week. The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug.
Expert insights. Personalized for you.
198 
Let's personalize your content